By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that its first-quarter 2010 net loss swelled 18 percent, as the firm's expenses for R&D, sales, and other purposes rose but its revenues continued to be insignificant.

The Tel Aviv, Israel-based firm, which uses an in silico prediction and selection platform for discovering drug and diagnostic candidates, had revenues of $125,000 for the three-month period ended Mar. 31, compared to no revenue for last year's first quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.